Validation of Treating to Non-Fasting Lipid Targets in Comparison to Fasting Lipid Targets
Completed
- Conditions
- 10011082hypercholesterolemiaHyperlipidemia10013317
- Registration Number
- NL-OMON41824
- Lead Sponsor
- Albert Schweitzer Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 352
Inclusion Criteria
Male and female patients, aged 18 years or older, from the outpatient department of Cardiology and Internal Medicine receiving lipid lowering therapy as secondary cardiovascular prevention are suitable for inclusion. Lipid lowering therapy is defined as the use of statins, fibrates, ezetimibe or nicotinic acid or a combination of these.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>-The number of patients that reach the set treatment target of LDL-C <2.5<br /><br>mmol/l when using non-fasting blood samples while their fasting LDL<br /><br>is>2.5mmol/l.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The number of patients that reach the set treatment target of apo B <0.8 g/l<br /><br>when using non-fasting blood samples and do not reach the target in fasting<br /><br>blood samples.<br /><br><br /><br>The number of patients who reach the set treatment target of<br /><br>non-HDL-C<3.3mmol/l when using non-fasting blood samples and do not reach the<br /><br>target in fasting blood samples.<br /><br><br /><br>Differences in morning and afternoon LDL-C levels.<br /><br><br /><br>Absolute differences in fasting and non-fasting LDL-C, direct LDL-C, apo B,<br /><br>non-HDL-C and triglycerides.<br /><br><br /><br>Absolute differences between calculated LDL-C, direct LDL-C and LDL-C using<br /><br>ultracentrifuge.</p><br>